Aurinia Pharmaceuticals Inc. provided earnings guidance for the fiscal year 2023. For the period, the company is narrowing its net product revenue guidance to a range of $155 million - $160 million for net product sales of LUPKYNIS. This guidance range is based on assumptions regarding PSF run rates, consistent conversion rates, time to convert, persistency and pricing.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.2 USD | +3.59% | +1.56% | -42.16% |
07/05 | Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value | CI |
02/05 | Transcript : Aurinia Pharmaceuticals Inc., Q1 2024 Earnings Call, May 02, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.16% | 716M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Earnings Guidance for the Fiscal Year 2023